NICE recommends Remicade and Humira for Crohn's disease
This article was originally published in Scrip
Executive Summary
NICE, the HTA body for England and Wales, has published draft guidance recommending Abbott's Humira (adalimumab) and Schering-Plough's Remicade (infliximab) for treating some NHS patients in England and Wales with Crohn's disease.